While the majority of oncogenic RAS mutations are in KRAS (commonly found in pancreas, lung, and colon carcinomas), bladder urothelial carcinomas, head and neck squamous cell carcinomas, and rhabdomyosarcomas more frequently harbor HRAS mutations20. The gene discussed is KRAS; the disease is bladder transitional cell carcinoma.